Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
-
- Lipika Goyal
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Funda Meric-Bernstam
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Antoine Hollebecque
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Juan W. Valle
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Chigusa Morizane
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Thomas B. Karasic
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Thomas A. Abrams
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Junji Furuse
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Robin K. Kelley
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Philippe A. Cassier
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Heinz-Josef Klümpen
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Heung-Moon Chang
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Li-Tzong Chen
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Josep Tabernero
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Do-Youn Oh
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Amit Mahipal
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Markus Moehler
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Edith P. Mitchell
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Yoshito Komatsu
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Kunihiro Masuda
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Daniel Ahn
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Robert S. Epstein
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Abdel-Baset Halim
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Yao Fu
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Tehseen Salimi
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Volker Wacheck
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Yaohua He
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Mei Liu
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- Karim A. Benhadji
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
-
- John A. Bridgewater
- From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
Journal
-
- New England Journal of Medicine
-
New England Journal of Medicine 388 (3), 228-239, 2023-01-19
Massachusetts Medical Society
- Tweet
Details 詳細情報について
-
- CRID
- 1360580229829780736
-
- ISSN
- 15334406
- 00284793
-
- Data Source
-
- Crossref
- KAKEN
